Investor Relations

4TH QUARTER/Full Year 2022


Evonik has published its quarterly report Q4/FY 2022 on March 2, 2023.

You can access further information here.

  • FY 2022 adj. EBITDA of €2.5 bn at lower end of outlook range: record first half followed by weak H2 with strong volume declines
  • Strong FCF finish: Active NWC management in Q4, strongest-ever quarterly FCF of €603 m – bringing FY cash conversion to >30%
  • Portfolio management on track: Divestments in Performance Materials progressing well
  • Innovation success story continues: FY 2022 with 20% sales growth in Innovation Growth Fields
  • Outlook FY 2023: Adj. EBITDA between €2.1 and 2.4 bn – Resilience in Specialty Additives, Health & Care and Smart Materials; lower prices in Animal Nutrition and Performance Materials

Reporting 4th Quarter/FY 2022

Link / PDF
Analyst & Investor Factsheet
Presentation Conference Call

Detailed overview of key financial data (Evonik Financials) - as PDF

Detailed overview of key financial data (Evonik Financials) - as Excel

Financial Report 2022

Sustainability Report 2022

Investor Relations News Q4/FY 2022

Analysts' consensus* (Vara Research)

Webcast Conference Call Q4/FY-Reporting
(March 2, 2023, 02.00 p.m. CET)

* The consensus is not controlled, changed or censored by Evonik Industries AG. Evonik Industries AG assumes no liability for the accuracy and completeness of these estimates and undertakes no obligation to update or revise such estimates and consensus data, even if they differ from Evonik Industries AG’s own forecasts or expectations. Evonik Industries AG is neither involved in the collection of the data, nor in the preparation of the consensus. This is done independently by Vara Research.